The association of biological markers with echocardiographic indices in patients with myocardial infarction with ST segment elevation and preserved left ventricular ejection fraction

Печерина, Т. Б.; Herman, A.; Chernobay, A G.; Каретникова, В. Н.; Груздева, О. В.; Kokov, А. N.; Поликутина, О. М.; Кашталап, В. В.; Barbarash, O. L.

doi:10.18087/cardio.2409

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In case of CAD and STEMI the factors that led to left ventricular adverse remodeling were analyzed and it was found that in majority of the cases vascular lesion coronary artery is the condition that lead to left ventricular remodeling in case of STEMI patients. Another study showed that OSM at first cause healing of myocardium by incomplete de-differentiation of cardio myocytes but it also has adverse effect as the extensive and prolong cardio myocytes de-differentiation cause ventricular dilation leading to heart failure and death of the patient [20][21] . In our studies it was found that OSM levels were quite high after the 24h of disease onset which led to adverse effects in the long run.…”

Section: Discussionmentioning

confidence: 99%

Association of Increased Oncostatin M with Adverse Left Ventricular Remodeling in Patients with Myocardial Infarction

Riaz¹,

Khalid²,

Ihsan³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: Myocardial infarction is the leading cause of death worldwide. Patients suffering from myocardial infarction with a ST-elevated segment termed as STEMI experience high risk of death and these patients report recurrent attacks even more as compared to other MI patients. Objective: The goal of this study was to check that either oncostatin M (OSM) can be used as a biomarker for the evaluation of myocardial infarction Study design: This control-experimental study was conducted in Biochemistry department of the Islam Medical College, Sialkot. Materials and methods: The study included 35 STEMI patients admitted in hospital, their oncostatin M level after 24 h of the onset of disease was calculated. The oncostatin M level after 6 months was later on analyzed. Electrocardiography was performed for all patients. The serum level was studied properly to look for level of biomarkers. The review board and ethical committee of the hospital approved the study. Results: OSM level was increased after 24h of the onset of the disease. There was reduction in the level of OSM when measured after 6 months but still the levels suggested that OSM was detectable in the serum and can be used as a biomarker for myocardial infarction. Conclusion: High levels of OSM in the serum after 24h can be attributed to its link with development of adverse LV remodeling among patients suffering from myocardial infarction. The OSM levels were decreased eventually but it was still high even after 6 months of the onset. Keywords: CAD, oncostatin M, myocardial infarction, STEMI

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Increased Oncostatin M with Adverse Left Ventricular Remodeling in Patients with Myocardial Infarction

Riaz¹,

Khalid²,

Ihsan³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…Определение ассоциации уровней sST2 с показателями систолической и диастолической функций ЛЖ подтверждено в ряде исследований и согласуется с нашими данными [13,14]. Это характеризует рассматриваемый белок как валидный биомаркер для выявления пациентов не только с ХСНсФВ, но и с ХСНснФВ, у которых уровни sST2 приобретают корреляцию с уровнями NT-proBNP [6].…”

Section: Discussionunclassified

Level and correlations of soluble suppression of tumorigenicity 2 protein in heart failure and its relationship with clinical and paraclinical characteristics of patients

Kravchenko

Budnevsky

Kontsevaya³

et al. 2022

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To establish the correlations of the soluble suppression of tumorigenicity 2 protein (sST2) and N-terminal pro-brain natriuretic peptide (NT-proBNP) with some clinical and paraclinical characteristics of patients with heart failure (HF).Material and methods. The study included 130 patients with HF (men — 54, women — 76, mean age, 64,3±8,3 years) from the regional registry of HF patients in the Voronezh Oblast. All patients underwent echocardiography and general clinical investigations. In addition, the serum levels of sST2 and NT-proBNP were determined and their correlations with other parameters were studied.Results. The blood level of sST2 in HF patients was 339,8 [266;405] pg/ml. In the study sample of patients with HF, sST2 levels correlated with right atrial (r=0,49) and right ventricular (r=0,32) sizes, left ventricular end-diastolic dimension (r=0,34) and volume (r=0,33), left ventricular early diastolic filling rate (r=-0,35), blood calcium level (r=-0,55) and functional class of exertional angina (r=-0,37).Conclusion. The data obtained may indicate a pathogenetic relationship between sST2 and systolic and diastolic dysfunction of the left ventricle and right heart.

show abstract

“…ST2 является одним из основных биомаркеров, сигнализирующим о наличии и тяжести неблагоприятного ремоделирования сердца и фиброзирования ткани, которые возникают при инфаркте миокарда, остром коронарном синдроме или прогрессировании сердечной недостаточности [5,6]. ST2 (Growth STimulation expressed gene 2, так же известный как IL1RL1 и Supression of tumorigenicity 2) -член семейства рецепторов интерлейкина-1, выполняет важную роль в регуляции иммунного и противовоспалительного ответов [7].…”

unclassified

Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders

Гракова

Kopeva

Teplyakov

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To study the role of soluble ST2 (sST2) in patients with coronary artery disease (CAD) and chronic heart failure (CHF) associated with carbohydrate metabolism disorders (impaired glucose tolerance (IGT) and type 2 diabetes mellitus (DM) in risk stratification of adverse cardiovascular events (ACE) for 12 months of follow-up. Materials and methods. We enrolled 118 patients with CAD and CHF I-III FC (NYHA) with the ejection fraction of left ventricular of 60 [46; 64] % aged 62.5 [57; 68] years. Serum sST2 levels were measured by enzyme immunoassay. Results. Depending on the presence of carbohydrate metabolism disorders (CMD), the patients were divided into 3 groups: group 1 (n=65) included patients without CDM, group 2 (n=30) included with IGT, and group 3 (n=23) included with type 2 DM. Serum levels of sST2 in patients with CMD were significantly (p=0.011) higher than in patients without CMD, but in subgroups of patients with IGT and type 2 DM, the concentrations of sST2 did not differ. In group 1 sST2 levels were 30.51 [26.38; 37.06] ng/ml, and in group 2 and 3 - 37.97 [33.18; 47.48] and 41.45 [35.27; 50.37] ng/ml, respectively. There were statistically significant differences in the rate of adverse ACE in relation to sST2 levels: in spite of CMD, in subgroups with biomarker overexpression adverse CCC occurred more often (p

show abstract

The association of biological markers with echocardiographic indices in patients with myocardial infarction with ST segment elevation and preserved left ventricular ejection fraction

Cited by 3 publications

References 0 publications

Association of Increased Oncostatin M with Adverse Left Ventricular Remodeling in Patients with Myocardial Infarction

Association of Increased Oncostatin M with Adverse Left Ventricular Remodeling in Patients with Myocardial Infarction

Level and correlations of soluble suppression of tumorigenicity 2 protein in heart failure and its relationship with clinical and paraclinical characteristics of patients

Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders

Contact Info

Product

Resources

About